longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Longeveron

LGVN

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -1.00, within the reasonable range, cheaper than 60.46% of the time in the past 3 years, and the industry ranks 177/601, the industry Median -2.50.

-0.996xP/E
$7.33Stock price
$-7.36Earnings per share
-0.996xP/E
Stock price$7.33Earnings per share$-7.36

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-0.92x
Typical range
-1.18x–-0.59x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-55.00x148.77%$178.21B
MRNAUSModerna
-18.24x15.47%$57.48B
CSLLYUSCSL Limited
-22.22x--$57.30B
NTRAUSNatera
-246.50x10.38%$47.41B
RVMDUSRevolution Medicines
-24.70x64.29%$43.68B
ROIVUSRoivant Sciences
-110.74x148.13%$29.49B
INSMUSInsmed
-32.29x74.55%$28.26B
BNTXUSBioNTech SE
-12.41x19.96%$24.30B
BBIOUSBridgebio Pharma
-20.47x28.57%$14.16B
SMMTUSSummit Therapeutics
-16.35x18.42%$14.00B
MDGLUSMadrigal Pharma
-37.99x50.86%$12.35B
ARWRUSArrowHead Pharma
-36.58x36,308.30%$11.70B
ABVXUSAbivax SA
-26.65x32.59%$10.34B
CYTKUSCytokinetics
-11.47x6.37%$10.26B
KYMRUSKymera Therapeutics
-31.91x4.94%$9.56B
PRAXUSPraxis Precision Medicines
-27.55x3.05%$9.34B
IONSUSIonis Pharma
-15.94x52.66%$9.01B
PCVXUSVaxcyte
-8.32x48.80%$8.85B
IBRXUSImmunityBio
-8.45x152.63%$8.38B
TWSTUSTwist Bioscience
-61.26x24.70%$8.38B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.